30 closest matches · ranked by relevance
Hypochondroplasia
Primary: Change From Baseline in Height-Standard Deviation Score (H-SDS) of Recombinant Human Growth Hormone (r-hGH) Treated Subjects at Year 3 — 1.39 Standard Deviation Score…
Pseudohypoparathyroidism · Albright Hereditary Osteodystrophy
Primary: Intelligence Quotient — 85.9; 104.3; 103.2 units on a scale
Short Stature
Primary: Height Standard Deviation Score — -2.52; -1.57; -1.19; -1.09 standard deviation score
Endocrine System Diseases
Primary: Change From Baseline in Annual Growth Rate Standard Deviation Score (SDS) for Chronological Age (CA) at Month 36 in Intent-to-Treat (ITT) Population — -1.29; 2.36 SDS
Obesity · Osteopenia
Primary: Bone Mineral Density — -0.015; -0.008 grams/cm^2
Achondroplasia
Primary: Annualized Height Velocity (cm/Year) After 52 Weeks of Double-blind Treatment — 4.09; 4.52; 5.16; 5.42 cm/year — p== 0.6004
Growth Hormone Deficiency · Septo-Optic Dysplasia · Hypopituitarism
Primary: Change in Anthropometric Measures Over Time — 1.97; -0.61; 1.39; 1.22 Z-score
Achondroplasia
Primary: Number of Participants With Adverse Events (AEs) by Severity Grade and Study Drug Treatment-emergent Adverse Events (TEAEs) — 11; 32; 32; 0 Participants
Fibrous Dysplasia Of Bone
Primary: Proportion of Participants With Serum Phosphate Levels Within the Target Range at Week 48 — 1 Proportion of participant
Hypopituitarism · Pituitary Insufficiency · Growth Hormone Deficiency, Adult
Primary: Clinically Significant Adverse Events — 2.58; 3.78; 4.0; 5.3 percentage of participants
Growth Disorders · Insulin-Like Growth Factor-1 Deficiency
Primary: Height Velocity During the First Year - Intent to Treat (ITT)Population — 5.2; 6.9; 7.7 cm/yr — p=<0.0001
Achondroplasia
Primary: Mean Height Growth at Month 3 — 1.11; 0.84; 0.75; 1.07 Ratio
Osteogenesis Imperfecta
Primary: Proportion of Subjects Who Met Criteria of Increase in Growth Rate Since Baseline. — 25 Participants
Short Stature
Primary: Height Velocity — 3.0; 4.3; 6.2; 4.8 cm/y
Phelan McDermid Syndrome
Primary: ABC - Social Withdrawal Subscale — 10.31; 4.6; 14.8; 6.2 score on a scale
Infant, Small for Gestational Age
Primary: Change From Baseline in Height Standard Deviation Score (SDS) at Month 24. — 1.63; 0.43 SDS — p=<0.001
Small for Gestational Age
Primary: Number of Participants With Treatment Related Adverse Events. — 44 participants
Short Stature Born Small for Gestational Age (SGA)
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 27; 31; 10; 5 participant
Growth Disorders · Intrauterine Growth Retardation
Primary: Change From Baseline in Annual Growth Rate Measured at 2 Years Following Treatment With Genotonorm — 3.07; 3.97; 2.84 cm/year — p=0.02922
Growth Hormone (GH) Deficiency · Short Stature Homeobox Containing Gene (SHOX) Deficiency · SHOX Deficiency-related Disorder
Primary: Type 2 Diabetes Mellitus in GH-treated Participants — 1; 9; 8 Incident Cases
Hunter Syndrome
Primary: Height Overall — 113.759; 108.143 centimeter (cm) — p== 0.011
Achondroplasia
Primary: Overall Summary of Adverse Events During Initial 6-Month Period — 8; 8; 10; 9 Participants
Idiopathic Short Stature
Primary: Absolute On-target Difference (AOTD) at 24 Months — 0.603; 0.625 Standard Deviation Score (SDS) — p=0.5762
Hypoparathyroidism
Primary: Requirements for Calcium Supplementation — 3.03; 1.66 grams per day of calcium supplementation
Turner Syndrome
Primary: Height Standard Deviation Score (SDS) (National Center for Health Statistics [NCHS]), Change From Baseline to Last Measurement, As Randomized Population — 0.09; 0.97…
Insulin-Like Growth Factor-1 Deficiency · Growth Disorders
Primary: Height Velocity From Pretreatment (Week 0) to Week 34 — 7.0 centimeters per year (cm/yr)
Prader-Willi Syndrome
Primary: Body Composition — 51.2; 48.5; 52.1 percentage of body fat — p=<0.05
AIDS · HIV Infections
Primary: Change in Visceral Adipose Tissue Area From Baseline to 18 Months — -22; -4 centimeters squared — p=0.049
Growth Hormone Deficiency
Primary: Total Score Related to Overall Life Interference Assessed at Baseline, Using Dyad Clinical Outcomes Assessment 1 (DCOA 1) Questionnaire — 29.5; 27.1 units on a scale
Hypophosphatasia
Primary: Effect of Asfotase Alfa Treatment on Skeletal Manifestations of Hypophosphatasia (HPP) — 2.00 scores on a scale